Induction of tumor-specific CTLs by intratumoral administration of AdNK4 and DCs.

(A-B) C57Bl/6 mice with 8-day established subcutaneous B16-F10 tumors received injection of AdNK4 (▪) or AdNull (▵) followed by the injection of DCs on day 11, or received injection of AdNK4 followed by the injection of PBS on day 11 (○). Spleen cells were isolated 10 days after the last treatment and restimulated in vitro for 5 days with mitomycin C–treated B16-F10 cells. B16-F10 (A) or E.G7-OVA (B) cells were used as targets to assay the cytotoxic function of effector cells. (C-D) This study was identical to that described in panels A and B, except that E.G7-OVA cells, the control targets in panels A and B, were used as the different tumor type. Ten days after the last treatment, the splenocytes were isolated, restimulated with mitomycin C–treated E.G7-OVA cells, and assayed as in panels A and B. Shown are data for E.G7-OVA targets (C) and B16-F10 targets (D). Each experiment included tumor-bearing wild-type mice without any treatment as a control (■). For all panels, results are shown as the means ± the standard error (n = 3 per data point), and E/T denotes effector-target ratio.